The antirheumatic drug leflunomide, also an AhR agonist, demonstrates potential antidiabetic effects by enhancing insulin sensitivity and reducing hyperglycemia, likely mediated through its AhR-dependent anti-inflammatory properties. The gene discussed is INS; the disease is Hyperglycemia.